Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled trial of tozadenant in levodopa-treated Parkinson's disease patients with end-of-dose wearing-off
2014-005630-60Phase 3Completed
- Sponsor
- Biotie Therapies
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing Tozadenant + levodopa with Placebo + levodopa (2 arms). Primary endpoint: Primary Efficacy Endpoint (Part A). Started Jul 2015; status: completed.
02
Drugs
tozadenant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2014-005630-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005630-60.